CME GROUP INC. (CME) Insider Transactions

Reported filing row; may be amended. Do not sum filings blindly.

References:

Reported filing row; may be amended. Do not sum filings blindly.

F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.00 to $303.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $305.11 to $305.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

References:

Reported filing row; may be amended. Do not sum filings blindly.

References:

Reported filing row; may be amended. Do not sum filings blindly.

F1 Reflects a change in the form of beneficial ownership from direct to indirect ownership via transfer to the Reporting Person's revocable living trust. This transaction is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934.

F2 Represents shares acquired pursuant to a broker-administered dividend reinvestment plan.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Reflects a change in the form of beneficial ownership from direct to indirect ownership via transfer to the Reporting Person's revocable living trust. This transaction is exempt from Section 16 pursuant to Rule 16a-13 under the Securities Exchange Act of 1934.

F2 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F3 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F3

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. This grant was determined based on the Reporting Person's role as of September 1, 2026 and prior to the effective date of his promotion to Senior Managing Director and General Counsel on September 11, 2026. Under CME Group's compensation program, the Reporting Person is entitled to a promotion-related equity grant in March 2027, which would be reported on a subsequent Form 4.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F1

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F2

Reported filing row; may be amended. Do not sum filings blindly.

F1 Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

F2 Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

References: F1